Lowering the HTT1a transcript as an effective therapy for Huntingtons disease
Papadopoulou, A. S.; Alterman, J.; Landles, C.; Smith, E. J.; Conroy, F.; Phillips, J.; Canibano-Pico, M.; Nita, I. M.; Osborne, G. F.; Iqbal, A.; Aldous, S. G.; Bondulich, M. K.; Gomez-Paredes, C.; Sathasivam, K.; O'Reilly, D.; Echeverria, D.; Bobkov, K.; Greene, J. R.; Aronin, N.; Khvorova, A.; Bates, G. P.
Show abstract
Lowering the levels of HTT transcripts has been a major focus of therapeutic development for Huntingtons disease (HD), but which transcript should be lowered? HD is caused by a CAG repeat expansion in exon 1 of the HTT gene, and the rate of somatic expansion of this CAG repeat throughout life is now known to drive the age of onset and rate of disease progression. As the CAG repeat expands, the extent to which the HTT mRNA is alternatively processed to generate the HTT1a transcript and highly aggregation-prone and pathogenic HTT1a protein increases. Several HTT-lowering modalities have entered clinical trials that either target both HTT and HTT1a together, or full-length HTT alone. We have developed siRNAs that target the Htt1a mouse transcript (634/486) and used these, together with a potent Htt-targeting siRNA (10150) to compare the efficacy of lowering either full-length Htt or Htt1a. zQ175 and wild-type mice were treated with 10150 or 634/486 alongside control groups at 2 months of age with treatment to 6 or 10 months, or at 6 months with treatment to 10 months. The siRNA potency and durability were most effective in the hippocampus. Whilst both strategies showed benefits, despite the greater potency of 10150, targeting Htt1a was more effective at delaying HTT aggregation and transcriptional dysregulation than targeting full-length Htt. These data support HTT-lowering strategies that are designed to target the HTT1a transcript, either alone, or together with lowering full-length HTT. One Sentence SummaryLowering HTT1a transcript levels delays the onset of molecular and neuropathological phenotypes in a knock-in mouse model of Huntingtons disease.
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Suppression of Huntington's Disease Somatic Instability by Transcriptional Repression and Direct CAG Repeat Binding 96%
- PMS1 as a target for splice modulation to prevent somatic CAG repeat expansion in Huntington's disease 94%
- CRISPR/Cas9-Mediated Excision of ALS/FTD-Causing Hexanucleotide Repeat Expansion in C9ORF72 rescues major disease mechanisms in vivo and in vitro 94%
Similar papers in this journal
- The inhibition of LSD1 via sequestration contributes to tau-mediated neurodegeneration 95%
- Loss of primary cilia and dopaminergic neuroprotection in pathogenic LRRK2-driven and idiopathic Parkinsons disease 94%
- Developmental HCN channelopathy results in decreased neural progenitor proliferation and microcephaly in mice 94%
Similar papers in this journal
- Astrocytic TDP-43 dysregulation impairs memory by modulating antiviral pathways and interferon-inducible chemokines 95%
- Huntingtin is an RNA-binding protein and participates in NEAT1-mediated paraspeckles 94%
- Identification of distinct pathological signatures induced by patient-derived α-synuclein structures in non-human primates 94%
Similar papers in this journal
- Familial ALS/FTD-associated RNA-Binding deficient TDP-43 mutants cause neuronal and synaptic transcript dysregulation in vitro 94%
- MCOLN1 gene-replacement therapy corrects neurologic dysfunction in the mouse model of mucolipidosis IV. 93%
- A pathogenic DYT-THAP1 dystonia mutation causes hypomyelination and loss of YY1 binding 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.